European Journal of Pediatrics

, Volume 155, Issue 4, pp 291–296 | Cite as

Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-α and interleukin-1β by peripheral blood monocytes in the acute phase of Kawasaki disease

  • Hiroyuki Suzuki
  • Shigeru Uemura
  • Shigenobu Tone
  • Tadashi Iizuka
  • Michio Koike
  • Kenji Hirayama
  • Jiro Maeda



In order to study the in vitro effects of intact immunoglobulin (Ig) and gamma-interferon (INF-γ) in patients with Kawasaki disease, the production of tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) was measured in peripheral blood monocytes (PBM) both before and after intravenous immunoglobulin (IVIG) therapy. Spontaneous production of TNF-α and IL-1β both before and after IVIG therapy was significantly higher than in healthy controls. Intact Ig enhanced in vitro the production of TNF-α and IL-1β both before and after IVIG therapy approximately 3–4 times as compared to the spontaneous production. INF-γ did not affect the production of the two cytokines. Ig enhanced IL-1β mRNA expression in PBM of KD by 3–8 times more than that of spontaneous production.


These results suggest that: (1) the mechanism of action of IVIG therapy in KD is not to cut down the production of inflammatory cytokines such as TNF-α and IL-1β andf that (2) the changes of these cytokine levels may be related to the clinical effectiveness of high dose IVIG.

Key words

Kawasaki disease Immunoglobulin therapy TNF-α IL-1β Macrophages/monocytes 









intravenous imm unoglobulin


Kawasaki disease


peripheral blood monocytes


tumour necrosis factor-α


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anderson JP, Anderson UG (1990) Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 71:372–376PubMedGoogle Scholar
  2. 2.
    Andersson UG, Bjork L, Skansen-Saphir U, Andersson JP (1993) Down-regulation of cytokine production and interleukin-2 receptor expression by pooled IgG. Immunology 79:211–216PubMedGoogle Scholar
  3. 3.
    Berkman SA, Lee ML, Gale RP (1990) Clinical use of intravenous immunoglobulins. Ann Intern Med 112:278–292PubMedGoogle Scholar
  4. 4.
    Debets JMH, Van Der Linden CJ, Dieteren IEM, Leeuwenberg JFM, Buurman WA (1988) Fc-receptor crosslinking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J Immunol 141:1197–1201PubMedGoogle Scholar
  5. 5.
    Dwyer JM (1992) Manipulating the immune system with immune globulin. N Engl J Med 326:107–116PubMedGoogle Scholar
  6. 6.
    Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, et al (1988) Peripheral blood monocyte/ macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 48:247–251PubMedGoogle Scholar
  7. 7.
    Furusho K, Kamiya T, Nakano H, Kiosawa N, Shinomyia K, Hayashida T, et al (1984) High dose intravenous gammaglobulin for Kawasaki disease. Lancet II:1055–1058Google Scholar
  8. 8.
    Gifford GE, Lohmann-Matthes ML (1987) Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide. J Natl Cancer Inst 78:121–124PubMedGoogle Scholar
  9. 9.
    Harada K, Yamaguchi H, Hase N, Sato T, Asai T, Tatara K, et al (1988) Intravenous gammaglobulin treatment in Kawasaki disease. Presented at the Third International Kawasaki Disease Symposium, Tokyo, Japan, Proceedings, pp 314–317Google Scholar
  10. 10.
    Iizuka T, Minatogawa Y, Suzuki H, Mutsumi Ito, Shigeru Nakamine, Yoshihumi Hatanaka, et al (1993) Urinary neopterin as a predictive marker of coronary artery abnormalities in Kawasaki syndrome. Clin Chem 39:600–604PubMedGoogle Scholar
  11. 11.
    Kawasaki T (1967) Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children: clinical observation of 50 cases. Jpn J Allergol 16:178–222Google Scholar
  12. 12.
    Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H (1974) A new infantile acute febrile mucokutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 54:271–276PubMedGoogle Scholar
  13. 13.
    Lang BA, Silverman ED, Laxer RM, Lau AS (1989) Spontaneous tumor necrosis factor production in Kawasaki disease. J Pediatr 115:939–943PubMedGoogle Scholar
  14. 14.
    Leung DYM, Cotran RS, Kurt-Jomes E, Burns JC, Newburger JW, Pober JS (1989) Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawsaki disease. Lancet II:1298–1302Google Scholar
  15. 15.
    Lin C-Y, Lin C-C, Hwang B, Chiang BN (1991) The changes of interleukin-2, tumor necrotic factor and gamman-interferon production among patients with Kawasaki disease. Eur J Pediatr 150:179–182PubMedGoogle Scholar
  16. 16.
    Ling Z-D, Yeoh E, Webb BT, Farrell K, Doucette J, Matheson DS (1993) Intravenous Immunoglobulin induces Interferon- and interleukin-6 in vivo. J Clin Immunol 13:302–309PubMedGoogle Scholar
  17. 17.
    Maury CPJ, Salo E, Pelkonen P (1989) Elevated circulating tumor necrosis factor-α in patients with Kawasaki disease. J Lab Clin Med 113:651–654PubMedGoogle Scholar
  18. 18.
    Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, et al (1986) The treatment of Kawasaki syndrome with intravenous gammaglobulin. N Engl J M 315:341–347PubMedGoogle Scholar
  19. 19.
    Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al (1991) A single intravenous infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639PubMedGoogle Scholar
  20. 20.
    Okuni M, Harada K, Yamaguchi H, Yanagawa H, Sonobe T, Kawasaki T (1987) Intravenous Gammaglobulin therapy in Kawasaki disease: trial of low-dose gamma globulin. In: Shulman ST (ed) Kawasaki disease. Alan R Liss. New York, pp 433–439Google Scholar
  21. 21.
    Pål Aukrust, Stig S. Frøland, Nina-Beate Liabakk, Fredrik Müller, Ingvild Nordøy, Charlotte Haug, Terje Espevik (1994) Release of cytokines, soluble cytokine receptors, and interleukine-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84:2136–2143PubMedGoogle Scholar
  22. 22.
    Research Committee on Kawasaki Disease (1984) Report of Subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesion in Kawasaki disease. Tokyo, Japan, Ministry of Health and Welfare, pp 55–66Google Scholar
  23. 23.
    Rosen FS (1993) Putative mechanisms of the effect of intravenous γ-globulin. Clin Immunol Immunopathol 67 [Suppl]:S41-S43PubMedGoogle Scholar
  24. 24.
    Rowley AH, Shulman ST (1991) Current therapy for acute Kawasaki syndrome. J Pediatr 118:987–991PubMedGoogle Scholar
  25. 25.
    Shigenobu Tone, Yuko Katoh, Hirokazu Fujimoto, Shin Togashi, Masako Yanazawa, Yoshihiro Kato, et al (1990) Exression of inhibin a-subunit gene during mouse gametogenesis. Differentiation 44:62–68PubMedGoogle Scholar
  26. 26.
    Shimozato T, Iwata M, Tamura N (1990) Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravnous use. Infect Immun 58:1384–1390PubMedGoogle Scholar
  27. 27.
    Shulman ST (1989) IVGG therapy in Kawsaki disease: mechanism of action. Clin Immunol Immunopathol 53:141–146Google Scholar
  28. 28.
    Suzuki H, Iizuka T, Uemura S, Koike M, Maeda J (1988) The pathophysiological significance of serum tumor necrosis factor in Kawasaki disease. Presented at the Third International Kawasaki Disease Symposium, Tokyo, Japan, Proceedings, pp 117–119Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Hiroyuki Suzuki
    • 1
  • Shigeru Uemura
    • 2
  • Shigenobu Tone
    • 3
  • Tadashi Iizuka
    • 2
  • Michio Koike
    • 2
  • Kenji Hirayama
    • 1
  • Jiro Maeda
    • 1
  1. 1.Department of Laboratory MedicineWakayama Medical CollegeWakayamaJapan
  2. 2.Department of PediatricsWakayama Medical CollegeWakayamaJapan
  3. 3.Department of BiochemistryWakakayama Medical CollegeWakayamaJapan

Personalised recommendations